Tag: vTv Therapeutics (VTVT.Q)

“A once-a-day pill that reduces HbA1c and improves time in range with continuous glucose monitoring, without increasing hypoglycemia or any signal for adverse events, is a big win for the future care of type 1 diabetes,” stated clinical researcher Dr. John Buse.